Source: Annual Congress 2004 - Treatment of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. A. Ghofrani, R. Voswinckel, F. Reichenberger, M. G. Kohstall, H. Olschewski, R. T. Schermuly, N. Weissmann, J. Y. Berney, W. Seeger, F. Grimminger (Giessen, Germany; Geneva, Switzerland). Comparison of acute hemodynamic effects of three different phosphodiesterase inhibitors in patients with pulmonary arterial hypertension. Eur Respir J 2004; 24: Suppl. 48, 4327

Member's Comments

No comment yet.

Related content which might interest you: Predictors of response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021 RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors Source: Eur Respir J, 50 (3) 1602425; 10.1183/13993003.02425-2016 Year: 2017 Effects of iloprost and the phosphodiesterase inhibitor tolafentrine on pulmonary vascular remodelling in chronic experimental pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 20s Year: 2003 Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Acute effect of sildenafil (PDE-5) on cardiopulmonary interactions in patients with pulmonary arterial hypertension (PAH) secondary to pulmonary fibrosis Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008 Effects of a novel azaindole-based Rho-kinase inhibitor on hemodynamics and pulmonary vascular remodelling in experimental pulmonary hypertension Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases Year: 2009 Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009 Effect of phosphodiesterase 5 inhibitor in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Current medical therapies in pulmonary arterial hypertension Source: Eur Respir Mon 2012; 57: 26-41 Year: 2012 Effect of PDE-5 inhibitor treatment in patients with interstitial lung disease and pulmonary hypertension Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases Year: 2011 RESPITE: Riociguat in pulmonary arterial hypertension patients with an inadequate response to phosphodiesterase type 5 inhibitors Source: International Congress 2016 – Clinic of pulmonary hypertension Year: 2016 Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition Source: Eur Respir J 2013; 42: 869-870 Year: 2013 HDAC inhibitor quisinostat reduces pulmonary vascular remodeling in experimentally induced pulmonary arterial hypertension Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Comparison of clinical characteristics in patients with pulmonary arterial hypertension and inoperable chronic thromboembolic pulmonary hypertension Source: Annual Congress 2008 - Pulmonary venous thromboembolic disease Year: 2008 Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Ventilation-perfusion relationships in severe pulmonary hypertension. Effects of acute and long-term treatment with prostacyclin Source: Eur Respir J 2001; 18: Suppl. 33, 253s Year: 2001 Experience with pulmonary selective vasodilator treatment in COPD with severe pulmonary hypertension Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease Year: 2011 Phosphodiesterase 1 upregulation in pulmonary arterial hypertension – target for anti-remodeling therapy Source: Eur Respir J 2006; 28: Suppl. 50, 159s Year: 2006